Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer - PubMed (original) (raw)

Review

Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer

Christine L Hann et al. Trends Mol Med. 2007 Apr.

Abstract

Over 95% of patients with small-cell lung cancer (SCLC) die within five years of diagnosis. The standard of care and the dismal prognosis for this disease have not changed significantly over the past 25 years. Some of the characteristics of SCLC that have defined it as a particularly virulent form of cancer -- rapid proliferation, excessive metabolic and angiogenic dependence, apoptotic imbalance and genetic instability -- are now being pursued as tumor-specific targets for intervention both in preclinical and early phase clinical studies. Here, we summarize areas of ongoing anti-cancer drug development, including classes of agents that target essential pathways regulating proliferation, angiogenesis, apoptotic resistance, chromosomal and protein stability, and cell-cell and cell-matrix interaction.

PubMed Disclaimer

Figures

Figure 1

Diverse cellular processes that contribute to malignant transformation are being targeted through the development of new therapeutics for SCLC. Key components of proliferative signaling pathways are shown here, including tumor-associated angiogenesis, cell-survival pathways, mediators of chromosomal stability and replication, protein folding and stability, and cell–cell and cell–matrix interactions.

Similar articles

• Biological heterogeneity of small cell lung cancer.
  Carney DN, Gazdar AF, Nau M, Minna JD. Carney DN, et al. Semin Oncol. 1985 Sep;12(3):289-303. Semin Oncol. 1985. PMID: 2996148 Review.
• Treatment of extensive stage small cell lung cancer.
  Kelly K. Kelly K. Cancer Treat Res. 2001;105:253-76. doi: 10.1007/978-1-4615-1589-0_10. Cancer Treat Res. 2001. PMID: 11224990 Review.
• The role of new targeted therapies in small-cell lung cancer.
  Rossi A, Maione P, Colantuoni G, Guerriero C, Gridelli C. Rossi A, et al. Crit Rev Oncol Hematol. 2004 Jul;51(1):45-53. doi: 10.1016/j.critrevonc.2004.02.003. Crit Rev Oncol Hematol. 2004. PMID: 15207253 Review.
• Novel approaches for the treatment of small cell lung cancer.
  Wakelee H, Kelly K. Wakelee H, et al. Hematol Oncol Clin North Am. 2004 Apr;18(2):499-518. doi: 10.1016/j.hoc.2004.01.001. Hematol Oncol Clin North Am. 2004. PMID: 15094184 Review. No abstract available.
• Expression of placental growth factor gene in lung cancer.
  Woo IS, Park MJ, Byun JH, Hong YS, Lee KS, Park YS, Lee JA, Park YI, Ahn HK. Woo IS, et al. Tumour Biol. 2004 Jan-Apr;25(1-2):1-6. doi: 10.1159/000077716. Tumour Biol. 2004. PMID: 15192305

Cited by

• Data-driven structural analysis of small cell lung cancer transcription factor network suggests potential subtype regulators and transition pathways.
  Ozen M, Lopez CF. Ozen M, et al. NPJ Syst Biol Appl. 2023 Oct 31;9(1):55. doi: 10.1038/s41540-023-00316-2. NPJ Syst Biol Appl. 2023. PMID: 37907529 Free PMC article.
• Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma.
  Lee MJ, Tomita Y, Yuno A, Lee S, Abrouk NE, Oronsky B, Caroen S, Trepel JB. Lee MJ, et al. Expert Opin Investig Drugs. 2021 Feb;30(2):177-183. doi: 10.1080/13543784.2021.1863947. Epub 2021 Jan 11. Expert Opin Investig Drugs. 2021. PMID: 33306414 Free PMC article. Clinical Trial.
• Landscape of transcriptional deregulation in lung cancer.
  Zhang S, Li M, Ji H, Fang Z. Zhang S, et al. BMC Genomics. 2018 Jun 5;19(1):435. doi: 10.1186/s12864-018-4828-1. BMC Genomics. 2018. PMID: 29866045 Free PMC article.
• No room for statins in the quest for survival benefits in small cell lung cancer.
  Facchinetti F, Tiseo M. Facchinetti F, et al. Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S131-S133. doi: 10.21037/tlcr.2018.03.07. Transl Lung Cancer Res. 2018. PMID: 29780705 Free PMC article. No abstract available.
• Treatment of limited disease small cell lung cancer: the multidisciplinary team.
  Glatzer M, Rittmeyer A, Müller J, Opitz I, Papachristofilou A, Psallidas I, Früh M, Born D, Putora PM. Glatzer M, et al. Eur Respir J. 2017 Aug 24;50(2):1700422. doi: 10.1183/13993003.00422-2017. Print 2017 Aug. Eur Respir J. 2017. PMID: 28838979 Review.

References

1. 1. American Cancer Society. Cancer Facts and Figures 2006. American Cancer Society; 2006.
2. 1. Navada S, et al. Temporal trends in small cell lung cancer: analysis of the national surveillance, epidemiology, and end-results (SEER) database. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. 2006;24 (18S):7082.
3. 1. Johnson BE, et al. Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4:602–622. - PubMed
4. 1. Micke P, et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res. 2003;9:188–194. - PubMed
5. 1. Blackhall FH, et al. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res. 2003;9:2241–2247. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal